Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

This Phase I dose escalation study will evaluate Procaspase Activating Compound-1 (PAC-1), a small molecule that activates procaspase -3 to caspase-3, resulting in apoptosis of cancer cells, in patients with advanced malignancies. As of March 1, 2019, only patients with neuroendocrine tumors will be enrolled in Component 1 of this study. PAC-1 is taken orally on days 1-21 of a 28-day cycle. The maximum tolerated dose (MTD) of PAC-1 (5 dose levels) will be determined using a modified-Fibonacci dose-escalation 3+3 design. Treatment continues until disease progression, unacceptable toxicity, physician discretion, or patient refusal.

Study Overview

• Status: Completed
• Conditions: Solid Tumor; Neuroendocrine Tumors; Pancreatic Neuroendocrine Tumor
• Intervention / Treatment: Drug: PAC-1

• Study Type: Interventional
• Enrollment (Actual): 48
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60612
      • University of Illinois at Chicago
  • Maryland
    • Baltimore, Maryland, United States, 21231
      • Johns Hopkins Kimmel Cancer Center
  • Minnesota
    • Saint Paul, Minnesota, United States, 55101
      • Regions Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 81 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female ≥ 18 years of age
2. Diagnosis of advanced solid tumor or hematologic malignancy (limited to lymphoma) that has failed or become intolerant to standard therapy
3. Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1, or lymphoma that fulfills the Deauville PET Criteria
4. Has an ECOG PS of 0, 1, or 2
5. Has total bilirubin < 1.5 mg/dL, serum albumin > 3.0 gm/dL, AST and ALT < 1.5 ULN or < 3 x ULN for subjects with known hepatic metastases
6. Has serum creatinine < 1.5 × ULN
7. Has hemoglobin ≥ 10 g/dL, ANC ≥ 1.5 × 109/L, and platelet count ≥ 100 × 109/L
8. Must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after capsule(s) administration
9. Must be willing and able to comply with study
10. Has read, understood, and signed the ICF
11. Women of childbearing potential must not be pregnant or breast-feeding. In addition, a medically acceptable method of birth control must be used or total abstinence. Women who are postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be WOCP
12. Men who are not surgically or medically sterile must agree to use an acceptable method of contraception. Male patients with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must agree to use condoms at least one month after the last dose of study drug. Total abstinence for the same study period is an acceptable alternative
13. Prior systemic treatments for metastatic disease are permitted but may not be ongoing, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy
14. Willingness to donate blood for biomarker studies related to the type of therapies used in this trial and the tumor types being treated

Exclusion Criteria:

1. Had surgery within 4 weeks prior to study treatment except for minor procedures (hepatic biliary stent placement is allowed)
2. Gliomas are excluded, as well as any history of brain metastases, seizures or underlying brain injury
3. May not have received cytotoxic chemotherapy, targeted therapies, biologic response modifiers, chemotherapy, and hormonal therapy within the last 3 weeks, or nitrosureas within the last 6 weeks prior to study treatment.
4. Has a history of blood clots, pulmonary embolism, or DVT unless controlled by anticoagulant treatment
5. Has a history of an arterial thromboembolic event within the prior six months including CVA, TIA, MI, or unstable angina
6. Has uncontrolled HIV or hepatitis B or C
7. Has any clinically significant infection
8. Has any other severe, uncontrolled medical condition, including uncontrolled DM or unstable CHF
9. Radiation therapy to more than 25% of the bone marrow
10. Prior allogeneic bone marrow or organ transplantation
11. > Grade 1 peripheral neuropathy within 14 days before enrollment.
12. Patient has received other investigational drugs with 14 days before enrollment
13. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation
14. Abnormalities on 12-lead electrocardiogram (ECG) considered by the investigator to be clinically significant (such as acute ischemia, left bundle branch block, ventricular arrhythmias) or baseline prolongation of the rate-corrected QT interval (e.g., repeated demonstration of QTc interval > 480 milliseconds)
15. Presence of any non-healing wound, fracture, or ulcer
16. Has any condition that, in the opinion of the investigator, might jeopardize the safety of the patient or interfere with protocol compliance
17. Has any mental or medical condition that prevents the patient from giving informed consent

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Open label; Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.	Drug: PAC-1; PAC-1 is taken orally on days 1-21 of a 28-day cycle.; Other Names: Procaspase Activating Compound-1

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Tolerated Dose	The primary objective of this study component is to determine the maximum tolerated dose (MTD) of PAC-1 in patients with advanced, previously treated malignancy, by evaluation of toxicity and tolerability.	Up to 30 days post last dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Effects	Characterize adverse effects (AE) of PAC-1 in patients with advanced malignancy.	Up to 30 days post final dose
Disease Response based on RECIST Criteria for patients with solid tumors	Evaluate clinical response of PAC-1 in patients with solid tumors (RECIST v 1.1).	Up to 8 weeks following final dose
Disease Response based on Deauville PET Criteria for patients with lymphoma	Evaluate clinical response of PAC-1 in patients with lymphoma (Deauville PET Criteria).	Up to 8 weeks following final dose

Collaborators and Investigators

• Sponsor: Vanquish Oncology, Inc.
• Collaborators: University of Illinois at Chicago
• Investigators: Principal Investigator: Oana C Danciu, M.D., University of Illinois at Chicago

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2015
• Primary Completion (Actual): May 18, 2020
• Study Completion (Actual): May 18, 2020

Study Registration Dates

• First Submitted: January 30, 2015
• First Submitted That Met QC Criteria: February 3, 2015
• First Posted (Estimate): February 4, 2015

Study Record Updates

• Last Update Posted (Actual): September 24, 2020
• Last Update Submitted That Met QC Criteria: September 22, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Keywords: solid tumors; refractory; PNET; neuroendocrine; intolerant
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neoplasms; Neuroendocrine Tumors
• Other Study ID Numbers: 2015-0057